Novo CEO Doustdar Stays Bullish, Prioritizes Heritage in Rebrand
Novo's new CEO signals continuity over upheaval as the company rebrands after losing GLP-1 ground to Eli Lilly.
Medicine & Biotech
Clinical AI, drug discovery, devices, and regulatory approvals.